GlassScriptPhysician profile
Melissa Dail
NPI 1679822449
$3,139.43
in general payments reported to CMS, 2019-2025
38 companies · $510 in 2025
The $510 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $908 · 2022: $988 · 2023: $597 · 2024: $136 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $413.63 | 2021-2025 | |
| Novo Nordisk INC | $411.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $394.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $259.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.97 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $151.54 | 2021-2025 | Repatha, Tavneos, Otezla |
| Biohaven Pharmaceuticals, INC. | $145.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.64 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $134.94 | 2021-2023 | |
| Glaxosmithkline, LLC. | $133.18 | 2022-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $56.11 | 2022 | |
| Horizon Therapeutics Plc | $51.44 | 2021-2022 | |
| Astellas Pharma US INC | $49.54 | 2025 | Veozah |
| Seqirus USA INC | $49.33 | 2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $48.97 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Dail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.